The impact of GPCR structures on pharmacology and structure-based drug design
about
Physiology of the orexinergic/hypocretinergic system: a revisit in 2012Non-traditional roles of G protein-coupled receptors in basic cell biologyTurning a protein kinase on or off from a single allosteric site via disulfide trapping.In silico modeling of human α2C-adrenoreceptor interaction with filamin-23D structure prediction of human β1-adrenergic receptor via threading-based homology modeling for implications in structure-based drug designingNMR structures of polytopic integral membrane proteins.MQAPsingle: A quasi single-model approach for estimation of the quality of individual protein structure models.Progress in macromolecular crystallography depends on further miniaturization of crystallization experiments.Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.Structure-based discovery of A2A adenosine receptor ligands.hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.Emerging role of surface plasmon resonance in fragment-based drug discovery.Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach.Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features.Computational studies to predict or explain G protein coupled receptor polypharmacologyStabilization of G protein-coupled receptors by point mutations.Agonist dynamics and conformational selection during microsecond simulations of the A(2A) adenosine receptorModeling Protein-Ligand Binding by Mining Minima.Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.Predicting the biological activities through QSAR analysis and docking-based scoring.Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonistSmall Molecule Inhibited Parathyroid Hormone Mediated cAMP Response by N-Terminal Peptide Binding.Determining the Secondary Structure of Membrane Proteins and Peptides Via Electron Spin Echo Envelope Modulation (ESEEM) SpectroscopyDetergent-mediated protein aggregation.Proteins of the Hedgehog signaling pathway as therapeutic targets against cancer.Structure determination of membrane proteins in five easy piecesConserved activation pathways in G-protein-coupled receptors.In silico fragment-based drug design.Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed.Insights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes.Novel approaches for targeting the adenosine A2A receptor.Trapping small caffeine in a large GPCR pocket.Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions.Fragment-based lead discovery: challenges and opportunities.Ligand-dependent cholesterol interactions with the human A(2A) adenosine receptor.Phase-plate cryo-EM structure of a class B GPCR-G-protein complex.G protein-coupled receptors: computer-aided ligand discovery and computational structural analyses in the 2010s.Engineering an ultra-thermostable β(1)-adrenoceptor.Cross-pharmacology analysis of G protein-coupled receptors
P2860
Q26822470-4B3E3650-52D3-4135-97E5-7FC17925F760Q27006799-6EFCBFEC-D413-4234-9676-9D3E5CCC3492Q27667313-AB4E96CC-CAE5-47AE-BBEB-2C6B9B8237EEQ28392073-D9B41049-26DE-4392-9E99-125164EF68A0Q28546076-F599F2EE-B45F-4740-9B37-1C837AD11E8AQ30155502-C1CF1F8C-8018-471F-A925-B90FDED4ACA8Q30372373-AF084BCE-ED6F-40E2-AB32-633047405F1DQ30383389-134351DD-A5A9-4741-94C6-75AC190F1710Q30406301-DCE6FD67-CEF8-4905-B75D-3608AE248F30Q33560239-30FC4D99-F22A-47CF-8698-594741B364C2Q33733994-56A1C44B-0DA1-4811-ADF0-EDE560C6E15DQ34049517-B04B921A-B595-4826-83E4-2E830541B8EEQ34054370-220913E8-C45A-42E3-BED4-F03C610A543BQ34502788-D3A916C0-D784-4B71-82BE-167487809F7CQ35039998-8A545449-31CD-4139-B244-37BAE215807BQ35486811-D2023F36-086E-42C6-A1FB-12B0F5737BE4Q35926130-C8184B3F-F928-48F0-B7F9-AEBDB5746CAFQ35987132-B19A5415-5DFC-4B73-85C7-911A93ACEB31Q36109893-C7CA7BCE-5008-41CC-AFC8-AD29AD2CA3AEQ36242719-C612B8A7-DA2D-45BB-A774-9C6E341AAF4CQ36385052-FD2707B4-9685-400C-AC59-3D6410C430FDQ36638232-08996F38-6CA3-456B-8DEA-823CE6D13DA4Q36748441-F2442DC0-0BE3-4F1D-953A-E1BB26DE7DE2Q37222622-B696DE00-D458-4EAF-B7B0-CA6BD69EB0C5Q37775040-8B8F771B-27E7-495D-A531-982C6371CC5FQ37941436-23C5DB10-B1F1-4901-9759-6ECDFA658E4DQ37995724-FF8ADFB5-F9E4-41A7-9572-FED4DD3E6DA4Q38029118-647596D8-FEE1-4D90-8AFC-6017695B21C0Q38031832-D911080F-C18B-4612-8908-9BE5351BA6ABQ38138610-9A287D66-D8C4-42A0-97D1-3C1E6B0E5B5FQ38247995-3DC88B1B-31FA-4BE7-AF38-7960D87B2B67Q38259766-9580A4FA-985B-4E7E-A61A-3FD1A7691064Q38757851-9DDCB428-1E96-4F16-A6B4-6C73AB4B809CQ39043093-8F0FF12D-85D4-49C2-A672-52DD5E71549EQ39731911-6F7B7BCF-9AF3-4981-85CB-FD106C586213Q40647572-D0F513A8-64CF-40E3-AF7D-AB2325C01D91Q41598194-6E1C1641-A629-4290-88CB-05BCB6064D08Q41692321-D1BB1C06-6231-47E6-93D3-6EE5AD4D9C63Q41873089-59A5B11C-3273-4278-AA1A-054D6074EAC1Q41875668-14660C0B-8B4C-4782-A44E-8A07A64465FA
P2860
The impact of GPCR structures on pharmacology and structure-based drug design
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The impact of GPCR structures on pharmacology and structure-based drug design
@ast
The impact of GPCR structures on pharmacology and structure-based drug design
@en
The impact of GPCR structures on pharmacology and structure-based drug design
@nl
type
label
The impact of GPCR structures on pharmacology and structure-based drug design
@ast
The impact of GPCR structures on pharmacology and structure-based drug design
@en
The impact of GPCR structures on pharmacology and structure-based drug design
@nl
prefLabel
The impact of GPCR structures on pharmacology and structure-based drug design
@ast
The impact of GPCR structures on pharmacology and structure-based drug design
@en
The impact of GPCR structures on pharmacology and structure-based drug design
@nl
P2860
P1476
The impact of GPCR structures on pharmacology and structure-based drug design
@en
P2093
Miles Congreve
P2860
P304
P356
10.1111/J.1476-5381.2009.00476.X
P407
P577
2010-03-01T00:00:00Z